Novavax says it may start making vaccines targeting the omicron version in january

Novavax is "evaluating its vaccine against the Omicron variant"

The company is also developing an omicron-specific formulation of its SARS-CoV-2 spike protein antigen

Omicron coronavirus variant has caused turmoil in the global market

Novavax Inc on Thursday said it will start production of a COVID-19 vaccine designed to combat the Omicron coronavirus variant in January next year. In the meantime, it will continue to test whether its current vaccine is effective.

The company said, “Novavax is rapidly responding to the emergence of the latest potential threat of SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VoC). The company is pursuing a two-pronged variant strategy,” said the company. in a press release.

“First, Novavax is evaluating its vaccine against Omicron variants, as the company has done for previous variants, including alpha, beta, and delta. Second, Novavax has initiated the development of an Omicron-specific vaccine formulation. "

According to Novavax, expected lab data in the coming weeks will show whether antibodies from individuals who have already received the company's COVID-19 shot are capable of neutralizing variants.

The firm is also developing an omicron-specific formulation of its SARS-CoV-2 spike protein antigen, and in a few weeks, it will begin laboratory trials of a vaccine targeting the variant.

“Novavax is conducting ongoing studies to evaluate multiple variants, and we are encouraged by our current and ongoing data showing efficacy and safety against variants of interest (VOIs) and VOCs. Based on this, we will evaluate whether there are immune responses induced by Envx.-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine, which will offer similar cross-protection against Omicron as seen with other variants.

It further announced: "Novavax will begin testing whether antibodies from previously vaccinated individuals can neutralize the Omron variant with laboratory-based data expected in the coming weeks. Of participants in Novavax's clinical trials. Clinical samples will be evaluated as samples and viral reagents are available, and we will work diligently to expedite this analysis. Additionally, we plan to test whether Whether antibodies to the vaccine can inhibit omicron-HACE2 receptor binding (a step that is essential in the viral invasion process).

The Omicron coronavirus variant has caused turmoil and alarm in the global market over concerns about their potential to evade the protection provided by widely used vaccines and exacerbate a public health crisis.

In early November, Novavax received approval for its COVID-19 vaccine in Indonesia, soon followed by the Philippines.

Watch Times Now Live TV for the latest and breaking news from India and around the world.

You Can Also Visit My Previous Post :

• मधुमेह में खाएं यह कुदरती चीजें
• बैंक के ग्राहकों को लगा तगड़ा झटका
• करीब आ रहा है लॉकडाउन